DATATRAK Files Patent Infringement Lawsuit Against Medidata Solutions

DATATRAK Files Patent Infringement Lawsuit Against Medidata Solutions

Global eClinical Solutions Leader Enforces Unifying Data Patent
CLEVELAND, June 6, 2011 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced it has served a complaint for patent infringement on Medidata Solutions, Inc. for unauthorized use of DATATRAK's intellectual property in the Medidata Rave® platform. The patented technologies, as described in U.S. Patent No. 7,464,087, cover methods and systems for unifying data from a plurality of heterogeneous databases with each having business-context related data and a data access mechanism. DATATRAK's lawsuit was filed in the United States District Court for the Northern District of Ohio.

"As a leading innovator in eClinical solutions, DATATRAK has invested heavily in Research and Development in an effort to better serve our clients and to maintain a competitive advantage in the clinical trial market space. Thus, we will not permit Medidata or any other competitor to infringe on our innovative technologies. As the FDA provides guidance to the industry on the collection and storage of clinical trial data in a manner that realizes the benefits of a system with a unified database, like DATATRAK ONETM, it is not surprising that competitors would attempt to modify their systems to provide a unified experience. However, as the market shifts towards systems with the advantages of a unified database, DATATRAK insists our competitors respect our intellectual property rights," said Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "The patent is an important asset in DATATRAK's technology portfolio, and we vigorously protect our intellectual property."

Birch continued, "After months of attempting, with little success, to engage proactively with Medidata and its counsel, it has become clear that the only way we will be able to obtain any relief from this apparent infringement is through litigation. We will seek both injunctive and monetary relief, asking the Court to order Medidata to cease all activities that violate DATATRAK's intellectual property rights and to pay damages for its infringement." 

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting ServicesTM group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the OTCQX Market announcing its results for the three-month period ending March 31, 2011. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.